Literature DB >> 17902287

Show me the evidence: using number needed to treat.

Leslie Citrome1.   

Abstract

This article reviews one of the basic tools of evidence-based medicine, the calculation and interpretation of Number Needed to Treat (NNT) and Number Needed to Harm (NNH). Especially appealing is the simplicity of extracting this information from journal articles that report binary outcomes, such as medication response or emergence of adverse events. On-line resources and calculators can help the clinician in determining confidence intervals for these metrics. After a discussion of absolute versus relative risk, P-values, and the mechanics of calculating NNT and NNH, the application of NNT and NNH to a large clinical trial, the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia, is described.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17902287     DOI： 10.1097/SMJ.0b013e3180f63246

Source DB:  PubMed          Journal:  South Med J        ISSN： 0038-4348            Impact factor:   0.954


  7 in total

1.  Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations.

Authors:  Hans-Jürgen Möller; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02       Impact factor: 5.270

2.  Interpreting and Applying the CATIE Results: With CATIE, context is key, when sorting out Phases 1, 1A, 1B, 2E, and 2T.

Authors:  Leslie Citrome
Journal:  Psychiatry (Edgmont)       Date:  2007-10

3.  Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.

Authors:  Richard N Rosenthal; Walter Ling; Paul Casadonte; Frank Vocci; Genie L Bailey; Kyle Kampman; Ashwin Patkar; Steven Chavoustie; Christine Blasey; Stacey Sigmon; Katherine L Beebe
Journal:  Addiction       Date:  2013-09-18       Impact factor: 6.526

4.  Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia.

Authors:  Srihari Gopal; Joris Berwaerts; Isaac Nuamah; Kasem Akhras; Danielle Coppola; Ella Daly; David Hough; Joseph Palumbo
Journal:  Neuropsychiatr Dis Treat       Date:  2011-03-08       Impact factor: 2.570

5.  Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.

Authors:  Sandra V Navarra; Boxiong Tang; Liangjing Lu; Hsiao-Yi Lin; Chi Chiu Mok; Paijit Asavatanabodee; Parawee Suwannalai; Heselynn Hussein; Mahboob U Rahman
Journal:  Int J Rheum Dis       Date:  2013-10-16       Impact factor: 2.454

Review 6.  Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder.

Authors:  X J Wen; L M Wang; Z L Liu; A Huang; Y Y Liu; J Y Hu
Journal:  Braz J Med Biol Res       Date:  2014-06-13       Impact factor: 2.590

7.  Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis.

Authors:  Jonathan I Silverberg; Eric L Simpson; April W Armstrong; Marjolein S de Bruin-Weller; Alan D Irvine; Kristian Reich
Journal:  Am J Clin Dermatol       Date:  2021-10-26       Impact factor: 7.403
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.